Immune responses to a recombinant glycoprotein e herpes zoster vaccine in adults aged 50 years or older

for the ZOE-50/70 Study Group

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background. The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B Adjuvant System, was highly efficacious in preventing herpes zoster in the ZOE-50 and ZOE-70 trials. We present immunogenicity results from those trials. Methods. Participants (ZOE-50: ≥50; ZOE-70: ≥70 years of age) received 2 doses of HZ/su or placebo, 2 months apart. Serum anti-gE antibodies and CD4 T cells expressing ≥2 of 4 activation markers assessed (CD42+) after stimulation with gE-peptides were measured in subcohorts for humoral (n = 3293) and cell-mediated (n = 466) immunogenicity. Results. After vaccination, 97.8% of HZ/su and 2.0% of placebo recipients showed a humoral response. Geometric mean anti-gE antibody concentrations increased 39.1-fold and 8.3-fold over baseline in HZ/su recipients at 1 and 36 months post-dose 2, respectively. A gE-specific CD42+ T-cell response was shown in 93.3% of HZ/su and 0% of placebo recipients. Median CD42+ T-cell frequencies increased 24.6-fold (1 month) and 7.9-fold (36 months) over baseline in HZ/su recipients and remained ≥5.6-fold above baseline in all age groups at 36 months. The proportion of CD4 T cells expressing all 4 activation markers increased over time in all age groups. Conclusions. Most HZ/su recipients developed robust immune responses persisting for 3 years following vaccination.

Original languageEnglish
Pages (from-to)1750-1760
Number of pages11
JournalJournal of Infectious Diseases
Volume217
Issue number11
DOIs
Publication statusPublished - 2018 Jun 1

Fingerprint

Herpes Zoster Vaccine
Subunit Vaccines
Glycoproteins
T-Lymphocytes
Placebos
Vaccination
Age Groups
Human Herpesvirus 3
Antibodies
Herpes Zoster

Keywords

  • Adjuvant system
  • GE subunit vaccine
  • Herpes zoster vaccine
  • Immunogenicity
  • Varicella-zoster virus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Immune responses to a recombinant glycoprotein e herpes zoster vaccine in adults aged 50 years or older. / for the ZOE-50/70 Study Group.

In: Journal of Infectious Diseases, Vol. 217, No. 11, 01.06.2018, p. 1750-1760.

Research output: Contribution to journalArticle

@article{5010ccdf68c04471913e5bc9e36062b2,
title = "Immune responses to a recombinant glycoprotein e herpes zoster vaccine in adults aged 50 years or older",
abstract = "Background. The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B Adjuvant System, was highly efficacious in preventing herpes zoster in the ZOE-50 and ZOE-70 trials. We present immunogenicity results from those trials. Methods. Participants (ZOE-50: ≥50; ZOE-70: ≥70 years of age) received 2 doses of HZ/su or placebo, 2 months apart. Serum anti-gE antibodies and CD4 T cells expressing ≥2 of 4 activation markers assessed (CD42+) after stimulation with gE-peptides were measured in subcohorts for humoral (n = 3293) and cell-mediated (n = 466) immunogenicity. Results. After vaccination, 97.8{\%} of HZ/su and 2.0{\%} of placebo recipients showed a humoral response. Geometric mean anti-gE antibody concentrations increased 39.1-fold and 8.3-fold over baseline in HZ/su recipients at 1 and 36 months post-dose 2, respectively. A gE-specific CD42+ T-cell response was shown in 93.3{\%} of HZ/su and 0{\%} of placebo recipients. Median CD42+ T-cell frequencies increased 24.6-fold (1 month) and 7.9-fold (36 months) over baseline in HZ/su recipients and remained ≥5.6-fold above baseline in all age groups at 36 months. The proportion of CD4 T cells expressing all 4 activation markers increased over time in all age groups. Conclusions. Most HZ/su recipients developed robust immune responses persisting for 3 years following vaccination.",
keywords = "Adjuvant system, GE subunit vaccine, Herpes zoster vaccine, Immunogenicity, Varicella-zoster virus",
author = "{for the ZOE-50/70 Study Group} and Cunningham, {Anthony L.} and Heineman, {Thomas C.} and Himal Lal and Olivier Godeaux and Roman Chlibek and Hwang, {Shinn Jang} and McElhaney, {Janet E.} and Timo Vesikari and Charles Andrews and Wonseok Choi and Meral Esen and Hideyuki Ikematsu and Choma, {Martina Kovac} and Karlis Pauksens and St{\'e}phanie Ravault and Bruno Salaun and Schwarz, {Tino F.} and Jan Smetana and Abeele, {Carline Vanden} and {Van den Steen}, Peter and Ilse Vastiau and Weckx, {Lily Yin} and Levin, {Myron J.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1093/infdis/jiy095",
language = "English",
volume = "217",
pages = "1750--1760",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Immune responses to a recombinant glycoprotein e herpes zoster vaccine in adults aged 50 years or older

AU - for the ZOE-50/70 Study Group

AU - Cunningham, Anthony L.

AU - Heineman, Thomas C.

AU - Lal, Himal

AU - Godeaux, Olivier

AU - Chlibek, Roman

AU - Hwang, Shinn Jang

AU - McElhaney, Janet E.

AU - Vesikari, Timo

AU - Andrews, Charles

AU - Choi, Wonseok

AU - Esen, Meral

AU - Ikematsu, Hideyuki

AU - Choma, Martina Kovac

AU - Pauksens, Karlis

AU - Ravault, Stéphanie

AU - Salaun, Bruno

AU - Schwarz, Tino F.

AU - Smetana, Jan

AU - Abeele, Carline Vanden

AU - Van den Steen, Peter

AU - Vastiau, Ilse

AU - Weckx, Lily Yin

AU - Levin, Myron J.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background. The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B Adjuvant System, was highly efficacious in preventing herpes zoster in the ZOE-50 and ZOE-70 trials. We present immunogenicity results from those trials. Methods. Participants (ZOE-50: ≥50; ZOE-70: ≥70 years of age) received 2 doses of HZ/su or placebo, 2 months apart. Serum anti-gE antibodies and CD4 T cells expressing ≥2 of 4 activation markers assessed (CD42+) after stimulation with gE-peptides were measured in subcohorts for humoral (n = 3293) and cell-mediated (n = 466) immunogenicity. Results. After vaccination, 97.8% of HZ/su and 2.0% of placebo recipients showed a humoral response. Geometric mean anti-gE antibody concentrations increased 39.1-fold and 8.3-fold over baseline in HZ/su recipients at 1 and 36 months post-dose 2, respectively. A gE-specific CD42+ T-cell response was shown in 93.3% of HZ/su and 0% of placebo recipients. Median CD42+ T-cell frequencies increased 24.6-fold (1 month) and 7.9-fold (36 months) over baseline in HZ/su recipients and remained ≥5.6-fold above baseline in all age groups at 36 months. The proportion of CD4 T cells expressing all 4 activation markers increased over time in all age groups. Conclusions. Most HZ/su recipients developed robust immune responses persisting for 3 years following vaccination.

AB - Background. The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B Adjuvant System, was highly efficacious in preventing herpes zoster in the ZOE-50 and ZOE-70 trials. We present immunogenicity results from those trials. Methods. Participants (ZOE-50: ≥50; ZOE-70: ≥70 years of age) received 2 doses of HZ/su or placebo, 2 months apart. Serum anti-gE antibodies and CD4 T cells expressing ≥2 of 4 activation markers assessed (CD42+) after stimulation with gE-peptides were measured in subcohorts for humoral (n = 3293) and cell-mediated (n = 466) immunogenicity. Results. After vaccination, 97.8% of HZ/su and 2.0% of placebo recipients showed a humoral response. Geometric mean anti-gE antibody concentrations increased 39.1-fold and 8.3-fold over baseline in HZ/su recipients at 1 and 36 months post-dose 2, respectively. A gE-specific CD42+ T-cell response was shown in 93.3% of HZ/su and 0% of placebo recipients. Median CD42+ T-cell frequencies increased 24.6-fold (1 month) and 7.9-fold (36 months) over baseline in HZ/su recipients and remained ≥5.6-fold above baseline in all age groups at 36 months. The proportion of CD4 T cells expressing all 4 activation markers increased over time in all age groups. Conclusions. Most HZ/su recipients developed robust immune responses persisting for 3 years following vaccination.

KW - Adjuvant system

KW - GE subunit vaccine

KW - Herpes zoster vaccine

KW - Immunogenicity

KW - Varicella-zoster virus

UR - http://www.scopus.com/inward/record.url?scp=85048621140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048621140&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiy095

DO - 10.1093/infdis/jiy095

M3 - Article

AN - SCOPUS:85048621140

VL - 217

SP - 1750

EP - 1760

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 11

ER -